FDA Lifts Restrictions on 12 Peptides, Boosting Hims & Hers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HIMS?
Source: stocktwits
- FDA Policy Change: Health and Human Services Secretary Robert F. Kennedy announced on social media that the FDA will lift the safety risk classification on 12 peptides, allowing compounding pharmacies to manufacture these substances, thereby opening new market opportunities for Hims & Hers.
- Analyst Optimism: Leerink analyst Michael Cherny views this lifting of restrictions as a means for Hims & Hers to fill the growth gap likely arising from its transition to commercial weight loss products, suggesting that while immediate revenue may not materialize, it provides a new avenue for future growth.
- Retail Sentiment Surge: On Stocktwits, retail sentiment around Hims stock jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing by 628%, indicating strong investor confidence in the company's future prospects.
- Positive Market Reaction: Shares of Hims & Hers closed up 12% on Thursday, marking its fourth consecutive day of gains, reflecting the market's positive response to the FDA's policy change and expectations regarding the company's potential in peptide products.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 24.290
Low
16.50
Averages
32.95
High
60.00
Current: 24.290
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Health Stock Rises on Peptide Policy Changes
- Policy Impact: Health Secretary Kennedy announced that the FDA will remove 12 peptides from the high-risk category, potentially allowing Hims & Hers Health (HIMS) to expand in the peptide market, leading to a 14% stock price increase.
- Expert Evaluation Meetings: Starting in July, the Pharmacy Compounding Advisory Committee will rigorously assess each peptide's scientific merits and safety, which may shift market demand away from black market products and enhance regulatory access.
- Positive Market Reaction: Retail sentiment around HIMS shifted from 'bearish' to 'bullish', with message volume increasing significantly, indicating strong market interest in peptides and investor hopes for stock prices to rise to $45 or even $100.
- Analyst Rating Discrepancies: Among the 15 analysts covering HIMS, only 3 rated it as 'Buy', while 12 maintained a 'Hold' rating, with a 12-month average price target of $24, reflecting a cautious outlook on the stock's future performance.
See More
FDA Lifts Restrictions on 12 Peptides, Boosting Hims & Hers
- FDA Policy Change: Health and Human Services Secretary Robert F. Kennedy announced on social media that the FDA will lift the safety risk classification on 12 peptides, allowing compounding pharmacies to manufacture these substances, thereby opening new market opportunities for Hims & Hers.
- Analyst Optimism: Leerink analyst Michael Cherny views this lifting of restrictions as a means for Hims & Hers to fill the growth gap likely arising from its transition to commercial weight loss products, suggesting that while immediate revenue may not materialize, it provides a new avenue for future growth.
- Retail Sentiment Surge: On Stocktwits, retail sentiment around Hims stock jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing by 628%, indicating strong investor confidence in the company's future prospects.
- Positive Market Reaction: Shares of Hims & Hers closed up 12% on Thursday, marking its fourth consecutive day of gains, reflecting the market's positive response to the FDA's policy change and expectations regarding the company's potential in peptide products.
See More
Hims & Hers Health Stock Rises 11.12% on FDA Review News
- Significant Stock Surge: Hims & Hers Health's stock rose by 11.12% to close at $26.98, primarily driven by the FDA's decision to review compounded peptide therapies, indicating strong market confidence in the company's growth potential.
- Surge in Trading Volume: The trading volume reached 74.6 million shares, exceeding the three-month average by 111%, suggesting a notable increase in investor interest and potentially signaling future market trends.
- Optimistic Market Outlook: With the FDA possibly lifting restrictions on 12 peptide drugs, Hims & Hers Health is well-positioned to enter this
See More
US Stocks Dip Slightly as Chipmakers Weigh on Market
- Market Performance: The S&P 500 index fell by 0.15%, the Dow Jones Industrial Average decreased by 0.06%, and the Nasdaq 100 dropped by 0.21%, indicating a slight market pullback after reaching new highs, particularly pressured by weakness in chipmakers.
- Economic Data: Initial jobless claims in the US fell by 11,000 to 207,000, indicating a stronger labor market than the expected 213,000; additionally, the Philadelphia Fed business outlook unexpectedly rose by 8.6 to a 15-month high of 26.7, reflecting potential economic recovery.
- Oil Price Fluctuations: WTI crude oil prices increased by over 1% as the US naval blockade of the Strait of Hormuz enters its fourth day, which could exacerbate global oil and fuel shortages, impacting future energy market stability.
- Earnings Season: Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the technology sector, the earnings growth is only 3%, the lowest in two years, indicating a cautious market outlook on profit growth.
See More
US Stocks Rise Slightly, Chipmakers Rebound
- Chipmaker Rebound: Taiwan Semiconductor Manufacturing Co raised its 2026 revenue forecast, reflecting strong AI demand, which led to a rebound in chipmakers, with ON Semiconductor up over 10% and AMD up over 5%, indicating renewed market confidence in tech stocks.
- Mixed Economic Data: Initial jobless claims fell to 207,000, below the expected 213,000, suggesting a strong labor market; however, manufacturing production unexpectedly declined by 0.1%, highlighting the unevenness of economic recovery, which could influence future policy decisions.
- Oil Price Surge Impact: WTI crude oil prices rose over 2% due to escalating tensions between Iran and the US, potentially exacerbating global oil and fuel shortages, which negatively affects airline and cruise line profitability, leading to declines in related stocks.
- Earnings Season Begins: Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the tech sector, growth is only expected at 3%, raising concerns about the profitability of non-tech stocks and potentially impacting investor confidence.
See More
Hims & Hers Health Eyes Peptides as Growth Potential Post-GLP-1
- Peptide Market Potential: Hims & Hers Health is focusing on peptides as a new growth opportunity to replace GLP-1 driven growth, with rising market demand despite limited clinical evidence, potentially opening new revenue streams for the company.
- FDA Review Process: The FDA plans to hold a Pharmacy Compounding Advisory Committee meeting in July 2026 to review the potential inclusion of peptides, providing Hims with a clearer regulatory path, although immediate revenue impact is not expected.
- Acquisition and Innovation: Hims made a significant move by acquiring a California-based peptide facility in February 2025, with CEO Andrew Dudum describing peptide demand as “future-facing innovation,” as the company actively explores expanding access to peptide therapies in alignment with FDA guidance.
- Positive Market Reaction: Following HHS Secretary Robert F. Kennedy's announcement of the FDA's review of peptides, Hims' shares rose to around $26, indicating investor interest in the peptide market potential, although it will take time to validate profitability.
See More
Hims & Hers Health Stock Rises on Peptide Policy Changes
- Policy Impact: Health Secretary Kennedy announced that the FDA will remove 12 peptides from the high-risk category, potentially allowing Hims & Hers Health (HIMS) to expand in the peptide market, leading to a 14% stock price increase.
- Expert Evaluation Meetings: Starting in July, the Pharmacy Compounding Advisory Committee will rigorously assess each peptide's scientific merits and safety, which may shift market demand away from black market products and enhance regulatory access.
- Positive Market Reaction: Retail sentiment around HIMS shifted from 'bearish' to 'bullish', with message volume increasing significantly, indicating strong market interest in peptides and investor hopes for stock prices to rise to $45 or even $100.
- Analyst Rating Discrepancies: Among the 15 analysts covering HIMS, only 3 rated it as 'Buy', while 12 maintained a 'Hold' rating, with a 12-month average price target of $24, reflecting a cautious outlook on the stock's future performance.
See More
FDA Lifts Restrictions on 12 Peptides, Boosting Hims & Hers
- FDA Policy Change: Health and Human Services Secretary Robert F. Kennedy announced on social media that the FDA will lift the safety risk classification on 12 peptides, allowing compounding pharmacies to manufacture these substances, thereby opening new market opportunities for Hims & Hers.
- Analyst Optimism: Leerink analyst Michael Cherny views this lifting of restrictions as a means for Hims & Hers to fill the growth gap likely arising from its transition to commercial weight loss products, suggesting that while immediate revenue may not materialize, it provides a new avenue for future growth.
- Retail Sentiment Surge: On Stocktwits, retail sentiment around Hims stock jumped from 'bullish' to 'extremely bullish' in the past 24 hours, with message volume increasing by 628%, indicating strong investor confidence in the company's future prospects.
- Positive Market Reaction: Shares of Hims & Hers closed up 12% on Thursday, marking its fourth consecutive day of gains, reflecting the market's positive response to the FDA's policy change and expectations regarding the company's potential in peptide products.
See More
Hims & Hers Health Stock Rises 11.12% on FDA Review News
- Significant Stock Surge: Hims & Hers Health's stock rose by 11.12% to close at $26.98, primarily driven by the FDA's decision to review compounded peptide therapies, indicating strong market confidence in the company's growth potential.
- Surge in Trading Volume: The trading volume reached 74.6 million shares, exceeding the three-month average by 111%, suggesting a notable increase in investor interest and potentially signaling future market trends.
- Optimistic Market Outlook: With the FDA possibly lifting restrictions on 12 peptide drugs, Hims & Hers Health is well-positioned to enter this
See More
US Stocks Dip Slightly as Chipmakers Weigh on Market
- Market Performance: The S&P 500 index fell by 0.15%, the Dow Jones Industrial Average decreased by 0.06%, and the Nasdaq 100 dropped by 0.21%, indicating a slight market pullback after reaching new highs, particularly pressured by weakness in chipmakers.
- Economic Data: Initial jobless claims in the US fell by 11,000 to 207,000, indicating a stronger labor market than the expected 213,000; additionally, the Philadelphia Fed business outlook unexpectedly rose by 8.6 to a 15-month high of 26.7, reflecting potential economic recovery.
- Oil Price Fluctuations: WTI crude oil prices increased by over 1% as the US naval blockade of the Strait of Hormuz enters its fourth day, which could exacerbate global oil and fuel shortages, impacting future energy market stability.
- Earnings Season: Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the technology sector, the earnings growth is only 3%, the lowest in two years, indicating a cautious market outlook on profit growth.
See More
US Stocks Rise Slightly, Chipmakers Rebound
- Chipmaker Rebound: Taiwan Semiconductor Manufacturing Co raised its 2026 revenue forecast, reflecting strong AI demand, which led to a rebound in chipmakers, with ON Semiconductor up over 10% and AMD up over 5%, indicating renewed market confidence in tech stocks.
- Mixed Economic Data: Initial jobless claims fell to 207,000, below the expected 213,000, suggesting a strong labor market; however, manufacturing production unexpectedly declined by 0.1%, highlighting the unevenness of economic recovery, which could influence future policy decisions.
- Oil Price Surge Impact: WTI crude oil prices rose over 2% due to escalating tensions between Iran and the US, potentially exacerbating global oil and fuel shortages, which negatively affects airline and cruise line profitability, leading to declines in related stocks.
- Earnings Season Begins: Q1 earnings for the S&P 500 are projected to rise by 12% year-over-year, but excluding the tech sector, growth is only expected at 3%, raising concerns about the profitability of non-tech stocks and potentially impacting investor confidence.
See More
Hims & Hers Health Eyes Peptides as Growth Potential Post-GLP-1
- Peptide Market Potential: Hims & Hers Health is focusing on peptides as a new growth opportunity to replace GLP-1 driven growth, with rising market demand despite limited clinical evidence, potentially opening new revenue streams for the company.
- FDA Review Process: The FDA plans to hold a Pharmacy Compounding Advisory Committee meeting in July 2026 to review the potential inclusion of peptides, providing Hims with a clearer regulatory path, although immediate revenue impact is not expected.
- Acquisition and Innovation: Hims made a significant move by acquiring a California-based peptide facility in February 2025, with CEO Andrew Dudum describing peptide demand as “future-facing innovation,” as the company actively explores expanding access to peptide therapies in alignment with FDA guidance.
- Positive Market Reaction: Following HHS Secretary Robert F. Kennedy's announcement of the FDA's review of peptides, Hims' shares rose to around $26, indicating investor interest in the peptide market potential, although it will take time to validate profitability.
See More
